Skip to main content

Immune Pharmaceuticals Value Stock - Dividend - Research Selection

Immune Pharmaceuticals

ISIN: US45254C2008, WKN: A2DQB0

Market price date: 30.11.-0001
Market price: 0,00 USD




Immune Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 11-04-2018
Cash flow
Net operating cash flow -11.559.000
Capital Expenditures -28.000
Free cash flow -11.587.000
Balance sheet
Total Equity 13.758.000
Liabilities & Shareholders equity 28.608.000
Income statement
Net income -17.889.000
Eps (diluted) -2,110
Diluted shares outstanding 10.000.000
Net sales/revenue 1

Fundamental ratios calculated on: 30-11--0001

Ratios
Key figures 30-11--0001
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI0,00
ROE0,00
Income statement
P/E0,00
Div. Yield0,00%
P/B0,00
P/S0,00


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolIMNP
Market Capitalization0,00 USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internetwww.immunepharma.com


Description of the company

Immune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company's segment is acquiring, developing and commercializing prescription drug products. Its Immuno-inflammation product pipeline includes bertilimumab, a fully human antibody targeting eotaxin-1, a regulator of immuno-inflammation; a portfolio of immune oncology products, and NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, for the treatment of atopic dermatitis and psoriasis. Its immuno-oncology pipeline includes Ceplene, a small molecule targeting the Histamine-2 Receptor to overcome immunosuppression in Acute Myeloid Leukemia and other malignancies. Azixa and crolibulin are vascular disrupting agents. NanomAbs is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.immunepharma.com